Caseware UK (AP4) 2024.0.164 2024.0.164 2024-11-302024-11-3022023-12-01falseThe principal activity of the company during the period was that of the provision of staff to other group entities2truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 13746464 2023-12-01 2024-11-30 13746464 2022-12-01 2023-11-30 13746464 2024-11-30 13746464 2023-11-30 13746464 c:Director1 2023-12-01 2024-11-30 13746464 c:Director2 2023-12-01 2024-11-30 13746464 c:RegisteredOffice 2023-12-01 2024-11-30 13746464 d:CurrentFinancialInstruments 2024-11-30 13746464 d:CurrentFinancialInstruments 2023-11-30 13746464 d:CurrentFinancialInstruments d:WithinOneYear 2024-11-30 13746464 d:CurrentFinancialInstruments d:WithinOneYear 2023-11-30 13746464 d:ShareCapital 2024-11-30 13746464 d:ShareCapital 2023-11-30 13746464 d:RetainedEarningsAccumulatedLosses 2024-11-30 13746464 d:RetainedEarningsAccumulatedLosses 2023-11-30 13746464 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-11-30 13746464 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2023-11-30 13746464 c:OrdinaryShareClass1 2023-12-01 2024-11-30 13746464 c:OrdinaryShareClass1 2024-11-30 13746464 c:OrdinaryShareClass1 2023-11-30 13746464 c:FRS102 2023-12-01 2024-11-30 13746464 c:AuditExempt-NoAccountantsReport 2023-12-01 2024-11-30 13746464 c:FullAccounts 2023-12-01 2024-11-30 13746464 c:PrivateLimitedCompanyLtd 2023-12-01 2024-11-30 13746464 2 2023-12-01 2024-11-30 13746464 e:PoundSterling 2023-12-01 2024-11-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 13746464









RAPPTA THERAPEUTICS (UK) LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 NOVEMBER 2024

 
RAPPTA THERAPEUTICS (UK) LTD
 
 
COMPANY INFORMATION


Directors
R Parekh 
S Sawhney 




Registered number
13746464



Registered office
Eighth Floor
6 New Street Square

New Fetter Lane

London

EC4A 3AQ




Accountants
Rawlinson & Hunter LLP
Chartered Accountants

Eighth Floor

6 New Street Square

New Fetter Lane

London

EC4A 3AQ





 
RAPPTA THERAPEUTICS (UK) LTD
 

CONTENTS



Page
Balance Sheet
 
1 - 2
Notes to the Financial Statements
 
3 - 6


 
RAPPTA THERAPEUTICS (UK) LTD
REGISTERED NUMBER: 13746464

BALANCE SHEET
AS AT 30 NOVEMBER 2024

2024
2023
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
1,580,056
1,082,306

Cash at bank and in hand
 5 
72
205,155

  
1,580,128
1,287,461

Creditors: amounts falling due within one year
 6 
(1,497,559)
(1,229,746)

Net current assets
  
 
 
82,569
 
 
57,715

Total assets less current liabilities
  
82,569
57,715

  

Net assets
  
82,569
57,715


Capital and reserves
  

Called up share capital 
 8 
100
100

Profit and loss account
  
82,469
57,615

  
82,569
57,715


Page 1

 
RAPPTA THERAPEUTICS (UK) LTD
REGISTERED NUMBER: 13746464
    
BALANCE SHEET (CONTINUED)
AS AT 30 NOVEMBER 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



S Sawhney
Director
Date: 4 August 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
RAPPTA THERAPEUTICS (UK) LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024

1.


General information

Rappta Therapeutics (UK) LTD is a private company, limited by shares, incorporated in England and Wales with registration number 13746464. The registered office address is Eighth Floor, 6 New Street Square, New Fetter Lane, London, EC4A 3AQ. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

  
2.2

Exemption from preparing consolidated financial statements

The company, and the group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and group are considered eligible for the exemption to prepare consolidated accounts. 

 
2.3

Going concern

The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. The company expects the continued support of the parent company, who has confirmed they will provide such financial support as is necessary for the company to meet its liabilities as they fall due and continue in operation for a period of at least twelve months from the date of signing of the financial statements of the company. 

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.5

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 3

 
RAPPTA THERAPEUTICS (UK) LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024

2.Accounting policies (continued)

 
2.6

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.10

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.


3.


Employees




The average monthly number of employees, including directors, during the year was 2 (2023 - 2).


4.


Debtors

2024
2023
£
£


Prepayments and accrued income
1,580,056
1,082,306


Page 4

 
RAPPTA THERAPEUTICS (UK) LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024

5.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
72
205,155



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Amounts owed to group undertakings
1,326,455
1,177,524

Corporation tax
14,217
14,614

Other taxation and social security
72,504
18,252

Other creditors
71,171
-

Accruals and deferred income
13,212
19,356

1,497,559
1,229,746



7.


Financial instruments

2024
2023
£
£

Financial assets


Financial assets measured at fair value through profit or loss
72
205,155




Financial assets measured at fair value through profit or loss comprise cash at bank and in hand.


8.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



100 (2023 - 100) Ordinary shares of £1.00 each
100
100



9.


Related party transactions

Amounts owed to group undertakings (Note 6), is an amount of £1,326,455 (2023 - £1,177,524) owed to Rappta Therapeutics OY which is the parent undertaking. This amount is unsecured, interest free and repayable on demand. 

Page 5

 
RAPPTA THERAPEUTICS (UK) LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024

10.


Controlling party

The ultimate parent undertaking and controlling party is Rappta Therapeutics OY, a company incorporated in Finland. 

 
Page 6